RxDoctor Payments Data

Margaret Siman, MD

Family Medicine · Staunton, VANPI 1225006729

Payments from drug & device makers

$3,145in general payments, 2019–2025

Across 198 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$793
  • Lilly USA, LLC$607
  • Amarin Pharma, Inc.$423
  • Novo Nordisk$296
  • AstraZeneca$232
  • Otsuka America Pharmaceutical, Inc.$206
  • plus $588 from 16 others

What the payments were for

  • Food & beverage$3,133100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,145 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$29,199
Medicare patients
103
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$90,291
AbrysvoRsv Vacc, Pref A And Pref B/Pf293$88,401
MounjaroTirzepatide71$87,362
OzempicSemaglutide34$53,909
ShingrixVaricella-Zoster Ge/As01b/Pf175$36,524
JardianceEmpagliflozin25$36,178
Nucynta ErTapentadol Hcl12$29,397
OxycontinOxycodone Hcl11$28,788
XareltoRivaroxaban19$18,850
FarxigaDapagliflozin Propanediol12$14,267
ArexvyRsvpref3 Antigen/As01e/Pf40$11,957
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf68$4,354
Oxycodone Hcl138$4,238
SynthroidLevothyroxine Sodium31$3,356
Doxepin Hcl16$3,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$793$178,692386 claims
Lilly USA, LLCMounjaro$607$87,36271 claims
Novo NordiskOzempic$296$53,90934 claims
Johnson & JohnsonXarelto$107$18,85019 claims
AstraZenecaFarxiga$232$14,26712 claims
AbbVieSynthroid$110$3,35631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Staunton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →